环磷酰胺联合利妥昔单抗治疗儿童难治性肾病综合征的效果观察

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (609 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Cyclophosphamide combined with Rituximab in the treatment of refractory nephrotic syndrome in children.Methods A total of 98 children with refractory nephrotic syndrome who were treated in the Affiliated BenQ Hospital of Nanjing Medical University from July 2019 to July 2021 were selected as the research objects.They were divided into control group (n=49) and combination group (n=49) by random number table method.The control group was treated with glucocorticoid+Tacrolimus+Cyclophosphamide,while the combination group were treated with Rituximab on the basis of the control group.After treatment,the clinical efficacy of the two groups was evaluated,the renal function and immune function of the two groups were compared before treatment and 1 month after treatment,and the adverse reactions of the two groups were compared.Results The total effective rate of the combination group was 95.92%,which was higher than 81.63%of the control group,and the difference was statistically significant (P＜0.05).After 1 month of treatment,the levels of serum creatinine (SCr),blood urea nitrogen (BUN),urinary protein and β2-microglobulin (β2-MC)in the two groups were lower than those before treatment,and the differences were statistically significant (P＜0.05).After 1 month of treatment,the levels of SCr,BUN,urine protein and β2-MC in the combination group were lower than those in the control group,and the differences were statistically significant (P＜0.05).The levels of CD20+B in the two groups after 1 month of treatment were lower than those before treatment,and the difference was statistically significant (P＜0.05),and the level of CD20+B in the combination group after 1 month of treatment was lower than that in the control group,and the difference was statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞0.05).Conclusion Clinical application of Cyclophosphamide combined with Rituximab in the treatment of children with refractory nephrotic syndrome can obtain better clinical efficacy,can effectively improve the level of renal function and immune function of children,and is helpful to the prognosis of children,without significantly increasing adverse reactions,which has clinical reference value.

Key words： Cyclophosphamide Rituximab Glucocorticoids Refractory nephrotic syndrome in children Renal function Immune function Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIA Wei

Cite this article:

XIA Wei. Observation on the effect of Cyclophosphamide combined with Rituximab in the treatment of refractory nephrotic syndrome in children[J]. 中国当代医药, 2023, 30(21): 71-75.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2023/V30/I21/71

[1]	赵智敏，成艳哲，杨玉秀，等.来氟米特与环孢素A 治疗原发性难治性肾病综合征临床效果与安全性的对比研究[J].中国医药，2021，16（2）：240-244.
[2]	Ishimori S，Ando T，Kikunaga K.Influenza virus vaccination in pediatric nephrotic syndrome significantly reduces rate of relapse and influenza virus infection as assessed in a nationwide survey[J].Sci Rep，2021，11（1）：23305.
[3]	任彦红，陈丹，张广超，等.他克莫司与环磷酰胺治疗儿童激素依赖/频复发型肾病综合征的效果比较[J].中国民康医学，2019，31（2）：66-68.
[4]	葛雯雯，丁桂霞.他克莫司治疗儿童难治性肾病综合征的研究进展[J].解放军预防医学杂志，2019，37（5）：193-195.
[5]	关广聚.难治性肾病综合征诊断标准[J].山东医药，1990，17（6）：44-45.
[6]	中华医学会儿科学分会肾脏学组.激素耐药型肾病综合征诊治循证指南（2016）[J].中华儿科杂志，2017，55（11）：805-809.
[7]	黄国萍.小剂量糖皮质激素结合不同药物治疗儿童难治性肾病综合征的疗效及对相关指标和肾功能的改善效果比较[J].中国妇幼保健，2021，36（18）：4264-4266.
[8]	吴颖妮，包瑛，王垒.环磷酰胺在儿童难治性肾病综合征的应用[J].中国妇幼健康研究，2019，30（10）：1327-1330.
[9]	黄基立，王港，许武红，等.激素联合不同免疫抑制剂治疗难治性肾病综合征[J].西部医学，2020，32（6）：892-895.
[10]	杨太旺，江云锋，王国斌，等.利妥昔单抗与环磷酰胺治疗儿童激素依赖型或耐药型肾病综合征对肾功能、血脂及凝血功能的影响[J].中国现代应用药学，2022，39（4）：529-533.
[11]	韩林珊，董丹.他克莫司联合环磷酰胺冲击治疗儿童激素依赖型肾病综合征的临床效果[J].中国当代医药，2021，28（16）：138-141.
[12]	郭景鸽.小剂量激素联合环孢素A 与环磷酰胺对膜性肾病治疗的临床疗效影响[J].中国药物与临床，2019，19（6）：974-976.
[13]	张涛，沈茜，徐虹，等.利妥昔单抗治疗儿童原发性难治性肾病综合征疗效及其影响因素的自身前后对照研究[J].中国循证儿科杂志，2018，13（3）：161-165.
[14]	黄敏，王晓霞，王晓春，等.极低剂量利妥昔单抗治疗原发性难治性肾病综合征的疗效及对肾功能、免疫球蛋白、Toll 样受体的影响[J].临床肾脏病杂志，2022，22（10）：827-833.
[15]	袁小强，张献朝，赵丽萍.大剂量环磷酰胺冲击疗法联合右归丸治疗激素耐药型脾肾阳虚证原发性肾病综合征疗效观察[J].新乡医学院学报，2022，39（6）：566-572.
[16]	彭琳，李萌，黄映红，等.环孢素A 联合激素治疗肾病综合征后致肾毒性的临床观察[J].中国医师杂志，2020，22（1）：127-129.
[17]	朱剑红.环磷酰胺联合利妥昔单抗注射液治疗儿童难治性肾病综合征的临床疗效及其对肾功能、免疫功能的影响[J].临床合理用药杂志，2022，15（6）：159-161.
[18]	李育梅，王悦，王松，等.尝试长疗程利妥昔单抗治疗难治性原发性膜性肾病一例[J].中国综合临床，2020，36（6）：561-563.
[19]	张义德，范亚平，王锋，等.利妥昔单抗治疗难治性特发性膜性肾病1 例随访18 个月[J].临床肾脏病杂志，2019，19（7）：544-546.
[20]	刘莹，高健.他克莫司与环磷酰胺治疗难治性肾病综合征患儿的效果比较[J].中国当代医药，2022，29（5）：13-17.